Cybin Inc. (CYBN) News
Filter CYBN News Items
CYBN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CYBN News Highlights
- CYBN's 30 day story count now stands at 2.
- Over the past 1 day, the trend for CYBN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CYBN News From Around the Web
Below are the latest news stories about CYBIN INC that investors may wish to consider to help them evaluate CYBN as an investment opportunity.
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy PotentialThe increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. |
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog ProgramTORONTO, December 06, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office ("USPTO") has granted U.S. patent 11,834,410 in support of its CYB003 program. |
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline ResultsTORONTO, December 05, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced the presentation of four posters at the American College of Neuropsychopharmacology ("ACNP") annual meeting taking place December 3-6, 2023, in Tampa, Florida. The data presented include topline data from its |
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg DosesTORONTO, November 30, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced positive Phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder ("MDD"). |
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York CityTORONTO, November 20, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it will discuss its topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder, as part of an R&D investor briefing featuring a ke |
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023TORONTO, November 16, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next generation psychedelic-based treatment options, today announced that it will host an R&D briefing on Thursday, November 30, 2023, in New York City, at 10:00am ET. |
Cybin Announces Poster Presentation at Neuroscience 2023 Annual MeetingTORONTO, November 15, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023 hosted by the Society for Neuroscience ("SFN") taking place November 11-15, 2022, in Washington, D.C. |
Cybin Reports Second Quarter Financial Results and Recent Business HighlightsTORONTO, November 15, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights. |
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional ShareholdersTORONTO, November 14, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previously announced underwritten offering (the "Offering"). In connection with the Offering, the Company issued an aggregate of 66,666,667 units of the Company (the "Units") at a price |
Cybin Announces up to US$64 Million Offering of UnitsTORONTO, November 10, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce a firm commitment underwritten offering (the "Offering") of 66,666,667 units of the Company (the "Units") to one of the Company’s largest existing institutional shareholders and new institutional investors at |